Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.

Bachleitner-Hofmann T, Sun MY, Chen CT, Liska D, Zeng Z, Viale A, Olshen AB, Mittlboeck M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Clin Cancer Res. 2011 Jan 1;17(1):122-33. doi: 10.1158/1078-0432.CCR-10-0253.

PMID:
21208906
2.

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.

Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Mol Cancer Ther. 2008 Nov;7(11):3499-508. doi: 10.1158/1535-7163.MCT-08-0374. Epub 2008 Oct 30.

PMID:
18974395
3.

Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.

Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin MJ.

Clin Cancer Res. 2011 Aug 15;17(16):5432-42. doi: 10.1158/1078-0432.CCR-11-0592. Epub 2011 Jun 29. Retraction in: Clin Cancer Res. 2017 Jan 15;23 (2):612.

PMID:
21715568
4.

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.

Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB.

Clin Cancer Res. 2008 Jan 1;14(1):240-8. doi: 10.1158/1078-0432.CCR-07-1667.

PMID:
18172276
5.

The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo.

Liu KS, Ding WC, Wang SX, Liu Z, Xing GW, Wang Y, Wang YF.

Oncol Rep. 2012 Jun;27(6):1904-10. doi: 10.3892/or.2012.1738. Epub 2012 Mar 22.

PMID:
22447251
6.

Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.

Rice JW, Veal JM, Barabasz A, Foley B, Fadden P, Scott A, Huang K, Steed P, Hall S.

Oncol Res. 2009;18(5-6):229-42.

PMID:
20225761
7.

Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.

Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA.

Neoplasia. 2011 Jan;13(1):12-22.

PMID:
21245936
8.

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, Anderson KC.

Blood. 2009 Jan 22;113(4):846-55. doi: 10.1182/blood-2008-04-151928. Epub 2008 Oct 23.

PMID:
18948577
9.

Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.

Ji F, Liu X, Wu Y, Fang X, Huang G.

Drug Des Devel Ther. 2015 Oct 19;9:5697-704. doi: 10.2147/DDDT.S89410. eCollection 2015.

PMID:
26543351
10.

SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.

Wang SX, Ju HQ, Liu KS, Zhang JX, Wang X, Xiang YF, Wang R, Liu JY, Liu QY, Xia M, Xing GW, Liu Z, Wang YF.

Biosci Biotechnol Biochem. 2011;75(8):1540-5. Epub 2011 Aug 7.

PMID:
21821931
11.

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.

Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR.

Mol Cancer Ther. 2012 Mar;11(3):660-9. doi: 10.1158/1535-7163.MCT-11-0754. Epub 2012 Jan 11.

PMID:
22238368
12.

PTEN reconstitution alters glioma responses to c-Met pathway inhibition.

Goodwin CR, Lal B, Ho S, Woodard CL, Zhou X, Taeger A, Xia S, Laterra J.

Anticancer Drugs. 2011 Oct;22(9):905-12. doi: 10.1097/CAD.0b013e3283484750.

PMID:
21654317
13.

The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.

Wang R, Shao F, Liu Z, Zhang J, Wang S, Liu J, Liu H, Chen H, Liu K, Xia M, Wang Y.

Chem Biol Interact. 2013 Sep 5;205(1):1-10. doi: 10.1016/j.cbi.2013.06.007. Epub 2013 Jun 15.

PMID:
23777986
14.

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.

Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Jänne PA, Engelman JA.

Cancer Res. 2011 Feb 1;71(3):1081-91. doi: 10.1158/0008-5472.CAN-10-1623. Epub 2011 Jan 25.

PMID:
21266357
15.

A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.

Meng L, Shu M, Chen Y, Yang D, He Q, Zhao H, Feng Z, Liang C, Yu K.

Cancer Biol Ther. 2014 Jun 1;15(6):721-34. doi: 10.4161/cbt.28409. Epub 2014 Mar 11.

PMID:
24618813
16.

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.

Petti C, Picco G, Martelli ML, Trisolini E, Bucci E, Perera T, Isella C, Medico E.

Oncotarget. 2015 Jan 1;6(1):221-33.

PMID:
25473895
17.

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB.

Cancer Res. 2003 Nov 1;63(21):7345-55.

PMID:
14612533
18.

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.

Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, Kawamori Y, Toyoda M, Kiyota N, Fujiwara Y, Minami H.

Invest New Drugs. 2013 Oct;31(5):1158-68. doi: 10.1007/s10637-013-9959-2. Epub 2013 Apr 9.

PMID:
23568717
19.

Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.

Musiani D, Konda JD, Pavan S, Torchiaro E, Sassi F, Noghero A, Erriquez J, Perera T, Olivero M, Di Renzo MF.

FASEB J. 2014 Sep;28(9):4055-67. doi: 10.1096/fj.13-247924. Epub 2014 Jun 5.

PMID:
24903273
20.

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.

Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.

Mol Cancer Ther. 2009 Dec;8(12):3296-306. doi: 10.1158/1535-7163.MCT-09-0538.

PMID:
19952121

Supplemental Content

Support Center